Compounding Group Sues FDA for Removing Lilly’s Weight Loss Drug from Shortage List
A drug compounding industry group on Monday sued the U.S. Food and Drug Administration over its decision to take Eli Lilly’s blockbuster weight loss and diabetes drugs off its list of medicines in short supply last week.
Shortages of drugs such as Lilly’s Mounjaro and Novo Nordisk’s Ozempic have fueled demand for compounding facilities’ own versions of the medicines.
In a lawsuit in Fort Worth, Texas federal court, the Outsourcing Facilities Association claims the FDA removed Lilly’s tirzepatide from the list even though it remains in short supply. Lilly sells the drug under the brand names Zepbound for weight loss and Mounjaro for diabetes.
Read more at Reuters >>